Epocrates https://prod.caas.epocrates.com/ en Lung Cancer Screening in Asymptomatic Pts | USPSTF, ACCP, ACS, AATS, etc Guideline Synthesis https://prod.caas.epocrates.com/e/guideline/10_15 <span class="field field--name-title field--type-string field--label-hidden">Lung Cancer Screening in Asymptomatic Pts | USPSTF, ACCP, ACS, AATS, etc Guideline Synthesis</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/441" typeof="schema:Person" property="schema:name" datatype="">switaschek</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 10/15/2020 - 23:17</span> <div class="field field--name-field-g-title-s field--type-string field--label-above"> <div class="field__label">Title (short)</div> <div class="field__item">Lung Cancer Screening in Asymptomatic Pts</div> </div> <div class="field field--name-field-g-published field--type-boolean field--label-above"> <div class="field__label">Do not Publish</div> <div class="field__item">Publish</div> </div> <div class="field field--name-field-guidelines-specialty field--type-entity-reference field--label-above"> <div class="field__label">Guidelines Specialty</div> <div class="field__items"> <div class="field__item"><a href="/taxonomy/term/2596" hreflang="en">Family Medicine/Primary Care</a></div> <div class="field__item"><a href="/taxonomy/term/2616" hreflang="en">Health Maintenance</a></div> <div class="field__item"><a href="/taxonomy/term/2651" hreflang="en">OB/Gyn</a></div> <div class="field__item"><a href="/taxonomy/term/2681" hreflang="en">Pulmonary Medicine</a></div> <div class="field__item"><a href="/taxonomy/term/2656" hreflang="en">Oncology</a></div> <div class="field__item"><a href="/taxonomy/term/2611" hreflang="en">Geriatric Medicine</a></div> </div> </div> <div class="field field--name-field-rec-title field--type-string-long field--label-above"> <div class="field__label">Key Points</div> <div class="field__item">Low-dose CT (LDCT) is widely accepted; don’t use CXR as screen. Age &amp; risk level thresholds to start/end screening vary: Many recommend starting @ 55 yo in current/former smokers w/ ≥30 pk-yr hx, but USPSTF recommends starting earlier &amp; @ lower smoking hx. Shared decision-making integral to pre-screen discussion on risk/harm balance. Screening doesn’t replace smoking cessation.</div> </div> <div class="field field--name-field-patient-type-labels field--type-string field--label-above"> <div class="field__label">Patient Type Label</div> <div class="field__item">Choose Patient Type</div> </div> <div class="field field--name-field-patient-type field--type-entity-reference field--label-above"> <div class="field__label">Patient Type</div> <div class="field__items"> <div class="field__item"><a href="/node/158881" hreflang="en">Age</a></div> <div class="field__item"><a href="/node/158646" hreflang="en">Age 50 54 yo</a></div> <div class="field__item"><a href="/node/158651" hreflang="en">Age 55 74 yo</a></div> <div class="field__item"><a href="/node/158656" hreflang="en">Age 75 77 yo</a></div> <div class="field__item"><a href="/node/158661" hreflang="en">Age 78 80 yo</a></div> <div class="field__item"><a href="/node/158666" hreflang="en">Age 80 yo</a></div> </div> </div> <div class="field field--name-field-g-reference field--type-entity-reference field--label-above"> <div class="field__label">Reference</div> <div class="field__item"><a href="/node/158821" hreflang="en">Peer reviewed &amp; based on multiple guidelines/recommendations from specialty societies/government agencies</a></div> </div> <div class="field field--name-field-g-celebrity field--type-entity-reference field--label-above"> <div class="field__label">Celebrity</div> <div class="field__item"><a href="/node/159536" hreflang="en">epocrates</a></div> </div> <div class="field field--name-field-g-keywords field--type-string field--label-above"> <div class="field__label">Keywords</div> <div class="field__item">lung cancer,screening lung cancer,screen,lung cancer prevention,tobacco,smoker cancer screen,lung cancer screen,LDCT</div> </div> Fri, 16 Oct 2020 02:17:37 +0000 switaschek 158641 at https://prod.caas.epocrates.com A young girl with a discolored finger https://prod.caas.epocrates.com/e/docalertquiz/06_24-3 <span class="field field--name-title field--type-string field--label-hidden">A young girl with a discolored finger</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1106" typeof="schema:Person" property="schema:name" datatype="" content="cbebout@athenahealth.com">cbebout@athena…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 06/24/2022 - 15:23</span> <div class="field field--name-field-daq-question field--type-string-long field--label-above"> <div class="field__label">Question Long Text</div> <div class="field__item">(BMJ)—A 3-year-old girl presented with a 1-month hx of progressive discoloration at the tip of her R index finger. No hx of injury or insect bite; no pain, pruritus, or paresthesia. Parents reported that the girl habitually rubbed her scalp with this finger. Exam: brown patch on tip of R index finger. No discoloration on other fingers, oral mucosa, teeth, or eyes. Finger range of motion normal. Application of 75% ethanol didn’t affect the discoloration. What’s the dx? </div> </div> <div class="field field--name-field-daq-image field--type-file field--label-above"> <div class="field__label">Image</div> <div class="field__items"> <div class="field__item"> <span class="file file--mime-image-png file--image"> <a href="/sites/epocrates/files/2022-06/06_38_all%20users_BMJ_small.png" type="image/png">06_38_all users_BMJ_small.png</a></span> </div> </div> </div> <div class="field field--name-field-daq-correct field--type-string field--label-above"> <div class="field__label">Correct Answer</div> <div class="field__item">Frictional dermatitis</div> </div> <div class="clearfix text-formatted field field--name-field-daq-filler field--type-text-long field--label-above"> <div class="field__label">Filler Answers</div> <div class="field__items"> <div class="field__item"><p>&lt;p&gt;Exogenous staining&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;Buerger disease&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;Pernio&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;Acral nevus&lt;/p&gt;</p> </div> </div> </div> <div class="field field--name-field-daq-response field--type-string-long field--label-above"> <div class="field__label">Response</div> <div class="field__item">The patient was diagnosed with frictional dermatitis caused by repetitive mechanical stress (habitual scalp rubbing). Frictional dermatitis is mainly diagnosed based on clinical findings. Dermoscopy can help in dx but depends primarily on the skill of the operator. Pinpoint hemorrhagic suffusions and parallel ridge pattern of pigmentation may be observed by dermoscopy. Drug tx isn’t needed for frictional dermatitis; ceasing the causative behavior is sufficient. The lesion had completely resolved 3 months after the patient stopped rubbing her scalp. To ensure cessation of this habit, the parents were asked to distract their daughter when she attempted to rub her scalp. The lesion hadn’t recurred by the 4-month follow-up visit. &lt;br&gt;&lt;/br&gt;&lt;i&gt;BMJ&lt;/i&gt; 2022;377:e070336</div> </div> Fri, 24 Jun 2022 18:23:05 +0000 cbebout@athenahealth.com 199636 at https://prod.caas.epocrates.com Primary series 6 11 yo 2 doses 50 g 28 days apart in moderately severely immunocompromised pts give 3rd dose 50 g 28 days after 2nd dose may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts https://prod.caas.epocrates.com/node/199631 <span class="field field--name-title field--type-string field--label-hidden">Primary series 6 11 yo 2 doses 50 g 28 days apart in moderately severely immunocompromised pts give 3rd dose 50 g 28 days after 2nd dose may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/23/2022 - 19:33</span> <div class="field field--name-field-pt-detail-long field--type-string-long field--label-above"> <div class="field__label">Detail (Long)</div> <div class="field__item">&lt;b&gt;Primary series (6-11 yo):&lt;/b&gt; 2 doses (50 μg), 28 days apart; in moderately-severely immunocompromised pts, give 3rd dose (50 μg) ≥28 days after 2nd dose; may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts</div> </div> Thu, 23 Jun 2022 22:33:41 +0000 vgreene 199631 at https://prod.caas.epocrates.com Primary series 6 mo 5 yo 2 doses 25 g 28 days apart in moderately severely immunocompromised pts give 3rd dose 25 g 28 days after 2nd dose may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts https://prod.caas.epocrates.com/node/199626 <span class="field field--name-title field--type-string field--label-hidden">Primary series 6 mo 5 yo 2 doses 25 g 28 days apart in moderately severely immunocompromised pts give 3rd dose 25 g 28 days after 2nd dose may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/23/2022 - 19:32</span> <div class="field field--name-field-pt-detail-long field--type-string-long field--label-above"> <div class="field__label">Detail (Long)</div> <div class="field__item">&lt;b&gt;Primary series (6 mo-5 yo):&lt;/b&gt; 2 doses (25 μg), 28 days apart; in moderately-severely immunocompromised pts, give 3rd dose (25 μg) ≥28 days after 2nd dose; may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts</div> </div> Thu, 23 Jun 2022 22:32:36 +0000 vgreene 199626 at https://prod.caas.epocrates.com Primary series 6 mo 4 yo 2 doses 3 g 21 days apart then 1 dose 3 g at least 8wk later may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts https://prod.caas.epocrates.com/node/199621 <span class="field field--name-title field--type-string field--label-hidden">Primary series 6 mo 4 yo 2 doses 3 g 21 days apart then 1 dose 3 g at least 8wk later may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/23/2022 - 19:15</span> <div class="field field--name-field-pt-detail-long field--type-string-long field--label-above"> <div class="field__label">Detail (Long)</div> <div class="field__item">&lt;b&gt;Primary series (6 mo-4 yo):&lt;/b&gt; 2 doses (3 μg), 21 days apart, then 1 dose (3 μg) at least 8wk later; may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts </div> </div> Thu, 23 Jun 2022 22:15:48 +0000 vgreene 199621 at https://prod.caas.epocrates.com No fruit or veggies for more than a year https://prod.caas.epocrates.com/e/docalertquiz/06_16 <span class="field field--name-title field--type-string field--label-hidden">No fruit or veggies for more than a year</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/1106" typeof="schema:Person" property="schema:name" datatype="" content="cbebout@athenahealth.com">cbebout@athena…</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/16/2022 - 15:43</span> <div class="field field--name-field-daq-question field--type-string-long field--label-above"> <div class="field__label">Question Long Text</div> <div class="field__item">(BMJ)—A man in his 50s presented with a 2-week hx of a large bruise on his L foot and a 2-month hx of a rash on his bilateral lower limbs. PMHx: HCV treated 3 years earlier; HIV on antiretrovirals; remote hx of alcohol and injection drug use. No trauma/fever/night sweats/weight loss/other bleeding. Exam: poor dentition, no effusion of L ankle. Labs: low Hgb; WBC/platelets/mean corpuscular volume, WNL. What’s the dx?</div> </div> <div class="field field--name-field-daq-image field--type-file field--label-above"> <div class="field__label">Image</div> <div class="field__items"> <div class="field__item"> <span class="file file--mime-image-png file--image"> <a href="/sites/epocrates/files/2022-06/06_28_all%20users_BMJ_small.png" type="image/png">06_28_all users_BMJ_small.png</a></span> </div> </div> </div> <div class="field field--name-field-daq-correct field--type-string field--label-above"> <div class="field__label">Correct Answer</div> <div class="field__item">Scurvy</div> </div> <div class="clearfix text-formatted field field--name-field-daq-filler field--type-text-long field--label-above"> <div class="field__label">Filler Answers</div> <div class="field__items"> <div class="field__item"><p>&lt;p&gt;Henoch-Schönlein purpura&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;Idiopathic thrombocytopenic purpura&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;Meningococcal septicemia&lt;/p&gt;</p> </div> <div class="field__item"><p>&lt;p&gt;Vitamin B12 deficiency&lt;/p&gt;</p> </div> </div> </div> <div class="field field--name-field-daq-response field--type-string-long field--label-above"> <div class="field__label">Response</div> <div class="field__item">The patient had been eating only ready-made meals and no fresh fruit or vegetables for the past year. His vitamin C level was &lt;5.7 μmol/L (normal range, 23-114 μmol/L), which confirmed the dx of scurvy. Perifollicular hemorrhages surrounding prominent hyperkeratotic follicles and corkscrew hairs, as seen in this patient, are pathognomonic of scurvy. Anemia is present in up to 75% of cases. Other clinical signs of vitamin C deficiency include gingival inflammation and bleeding, splinter hemorrhages, delayed wound healing, and joint swelling.&lt;br&gt;&lt;/br&gt;&lt;i&gt;BMJ&lt;/i&gt; 2021;375:n2511</div> </div> Thu, 16 Jun 2022 18:43:28 +0000 cbebout@athenahealth.com 199616 at https://prod.caas.epocrates.com ESC https://prod.caas.epocrates.com/node/199611 <span class="field field--name-title field--type-string field--label-hidden">ESC</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/16/2022 - 13:53</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">Eczema Society of Canada</div> </div> Thu, 16 Jun 2022 16:53:21 +0000 vgreene 199611 at https://prod.caas.epocrates.com TCS https://prod.caas.epocrates.com/node/199606 <span class="field field--name-title field--type-string field--label-hidden">TCS</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/16/2022 - 13:20</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">topical corticosteroid</div> </div> Thu, 16 Jun 2022 16:20:39 +0000 vgreene 199606 at https://prod.caas.epocrates.com TCI https://prod.caas.epocrates.com/node/199601 <span class="field field--name-title field--type-string field--label-hidden">TCI</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/16/2022 - 13:20</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">topical calcineurin inhibitor</div> </div> Thu, 16 Jun 2022 16:20:16 +0000 vgreene 199601 at https://prod.caas.epocrates.com SLIT https://prod.caas.epocrates.com/node/199596 <span class="field field--name-title field--type-string field--label-hidden">SLIT</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/user/391" typeof="schema:Person" property="schema:name" datatype="">vgreene</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 06/16/2022 - 13:19</span> <div class="field field--name-field-g-abbrev-desc field--type-string field--label-above"> <div class="field__label">Description</div> <div class="field__item">sublingual immunotherapy</div> </div> Thu, 16 Jun 2022 16:19:58 +0000 vgreene 199596 at https://prod.caas.epocrates.com